Needham & Company Initiates Coverage on NuPathe (PATH) with a 'Buy'; Zelrix Poised To Emerge As Differentiated Treatment Option In Migraine
Tweet Send to a Friend
Needham & Company initiates coverage on NuPathe Inc. (Nasdaq: PATH) with a Buy rating. PT $12.
Needham analyst says, "The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham analyst says, "The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
